Healthcare >> Analyst Interviews >> July 6, 2015

Opportunities in Regenerative Medicine, Cancer Immunotherapy Markets for Value Investors

Jason Kolbert
Jason Kolbert is Head of Health Care Research and a Senior Biotechnology Analyst at Maxim Group. Mr. Kolbert has worked extensively in the health care sector as Product Manager for a leading pharmaceutical company, a Fund Manager and as an Equity Analyst. Prior to joining Maxim Group, he spent seven years at Susquehanna International Group where he managed a health care fund and later founded SIG’s sellside biotechnology team. Previously, Mr. Kolbert served as the Health Care Strategist for Salomon Smith Barney. He is frequently quoted in Barron’s and is regularly featured on CNBC. Prior to beginning his Wall Street career, Mr. Kolbert served as a Product Manager for Schering-Plough in Osaka, Japan. He received a B.S. in chemistry from SUNY New Paltz, and an MBA from the University of New Haven. Profile
TWST: Could you explain what your coverage is?

Mr. Kolbert: Our coverage ranges from the microcap companies with very small market caps like Opexa (NASDAQ:OPXA) to very large-cap